title: Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
abstract: The Valsartan Amlodipine Randomized Trial (VART) was performed to compare the beneficial effects of valsartan and amlodipine on cardiovascular events in Japanese hypertensive patients. In this subanalysis of the VART, we assessed the relationship between home blood pressure (HBP) levels and cardiovascular events in the enrolled patients. We enrolled 1021 patients with mild-to-moderate hypertension in the VART. The participants were allocated randomly to either the valsartan group or the amlodipine group. The primary end point was a composite of all-cause death, sudden death, cerebrovascular events, cardiac events, vascular events and renal events. A total of 621 patients (valsartan group: 305 and amlodipine group: 316) completed the measurements of HBP (morning and evening) throughout the trial. Both the agents evenly and significantly lowered morning HBP and evening HBP throughout the trial. There was no significant difference in the primary end point between the two groups. However, we observed significant decreases in the left ventricular mass index and urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. There were no significant differences in HBP levels and the main outcome of the cardiovascular events between the valsartan and amlodipine groups. However, in the valsartan group, significant improvements in left ventricular hypertrophy and microalbuminuria were observed.
authors: Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. htakano-cib@umin.ac.jp
authors: H
authors: H
authors: Takano
authors: H
authors: H
authors: Hasegawa
authors: H
authors: H
authors: Narumi
authors: S
authors: S
authors: Shindo
authors: H
authors: H
authors: Mizuma
authors: Y
authors: Y
authors: Kuwabara
authors: Y
authors: Y
authors: Kobayashi
authors: I
authors: I
authors: Komuro
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000453:epidemiology / Q000517:prevention & control; D017311:Amlodipine / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000453:epidemiology / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044466:Asian People / Q000706:statistics & numerical data*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D002423:Cause of Death; D003404:Creatinine / Q000652:urine; D003645:Death, Sudden / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D006333:Heart Failure / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000959:Antihypertensive Agents; D013777:Tetrazoles; D017311:Amlodipine; D000068756:Valsartan; D003404:Creatinine; D014633:Valine